LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Seliciclib | 10.0 | uM | LJP5 | 3 | J01 | 72 | hr | 1657 | 1957 | 5505 | 0.3555 | 0.0778 |
BT-20 | Ruxolitinib | 10.0 | uM | LJP5 | 1 | O13 | 72 | hr | 1657 | 4093 | 5505 | 0.7434 | 0.6329 |
BT-20 | Ruxolitinib | 10.0 | uM | LJP5 | 2 | O13 | 72 | hr | 1657 | 3943 | 5505 | 0.7162 | 0.5939 |
BT-20 | Ruxolitinib | 10.0 | uM | LJP5 | 3 | O13 | 72 | hr | 1657 | 3918 | 5505 | 0.7116 | 0.5874 |
BT-20 | XL147 | 10.0 | uM | LJP5 | 1 | G07 | 72 | hr | 1657 | 2184 | 5505 | 0.3967 | 0.1368 |
BT-20 | XL147 | 10.0 | uM | LJP5 | 2 | G07 | 72 | hr | 1657 | 2146 | 5505 | 0.3898 | 0.1269 |
BT-20 | XL147 | 10.0 | uM | LJP5 | 3 | G07 | 72 | hr | 1657 | 2225 | 5505 | 0.4041 | 0.1474 |
BT-20 | Saracatinib | 10.0 | uM | LJP6 | 1 | D07 | 72 | hr | 1657 | 1969 | 5505 | 0.3576 | 0.0809 |
BT-20 | Saracatinib | 10.0 | uM | LJP6 | 2 | D07 | 72 | hr | 1657 | 2272 | 5505 | 0.4127 | 0.1596 |
BT-20 | Saracatinib | 10.0 | uM | LJP6 | 3 | D07 | 72 | hr | 1657 | 2398 | 5505 | 0.4356 | 0.1924 |
BT-20 | Selumetinib | 10.0 | uM | LJP6 | 1 | M07 | 72 | hr | 1657 | 5484 | 5505 | 0.9961 | 0.9944 |
BT-20 | Selumetinib | 10.0 | uM | LJP6 | 2 | M07 | 72 | hr | 1657 | 5672 | 5505 | 1.0302 | 1.0432 |
BT-20 | Selumetinib | 10.0 | uM | LJP6 | 3 | M07 | 72 | hr | 1657 | 5096 | 5505 | 0.9256 | 0.8935 |
BT-20 | Sirolimus | 10.0 | uM | LJP6 | 1 | L13 | 72 | hr | 1657 | 3731 | 5505 | 0.6777 | 0.5388 |
BT-20 | Sirolimus | 10.0 | uM | LJP6 | 2 | L13 | 72 | hr | 1657 | 3799 | 5505 | 0.6900 | 0.5565 |
BT-20 | Sirolimus | 10.0 | uM | LJP6 | 3 | L13 | 72 | hr | 1657 | 3867 | 5505 | 0.7024 | 0.5741 |
BT-20 | Sorafenib | 10.0 | uM | LJP6 | 1 | B07 | 72 | hr | 1657 | 2657 | 5505 | 0.4826 | 0.2597 |
BT-20 | Sorafenib | 10.0 | uM | LJP6 | 2 | B07 | 72 | hr | 1657 | 2647 | 5505 | 0.4808 | 0.2571 |
BT-20 | Sorafenib | 10.0 | uM | LJP6 | 3 | B07 | 72 | hr | 1657 | 3172 | 5505 | 0.5761 | 0.3935 |
BT-20 | SU11274 | 10.0 | uM | LJP5 | 1 | J07 | 72 | hr | 1657 | 2102 | 5505 | 0.3818 | 0.1155 |
BT-20 | SU11274 | 10.0 | uM | LJP5 | 2 | J07 | 72 | hr | 1657 | 2153 | 5505 | 0.3911 | 0.1287 |
BT-20 | SU11274 | 10.0 | uM | LJP5 | 3 | J07 | 72 | hr | 1657 | 2026 | 5505 | 0.3680 | 0.0957 |
BT-20 | Fedratinib | 10.0 | uM | LJP5 | 1 | L01 | 72 | hr | 1657 | 1722 | 5505 | 0.3128 | 0.0167 |
BT-20 | Fedratinib | 10.0 | uM | LJP5 | 2 | L01 | 72 | hr | 1657 | 1562 | 5505 | 0.2837 | -0.0249 |
BT-20 | Fedratinib | 10.0 | uM | LJP5 | 3 | L01 | 72 | hr | 1657 | 1822 | 5505 | 0.3309 | 0.0427 |